• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

估算有资格使用免疫检查点抑制剂药物的美国癌症患者的百分比。

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs.

机构信息

Division of Hematology and Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland.

Now with Center for Health Sciences, Oklahoma State University, Tulsa.

出版信息

JAMA Netw Open. 2020 Mar 2;3(3):e200423. doi: 10.1001/jamanetworkopen.2020.0423.

DOI:10.1001/jamanetworkopen.2020.0423
PMID:32150268
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7063495/
Abstract

This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.

摘要

本横断面研究估计了美国癌症患者中有资格使用免疫检查点抑制剂药物的比例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1d1/7063495/f58cbd97dff1/jamanetwopen-3-e200423-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1d1/7063495/f58cbd97dff1/jamanetwopen-3-e200423-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1d1/7063495/f58cbd97dff1/jamanetwopen-3-e200423-g001.jpg

相似文献

1
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs.估算有资格使用免疫检查点抑制剂药物的美国癌症患者的百分比。
JAMA Netw Open. 2020 Mar 2;3(3):e200423. doi: 10.1001/jamanetworkopen.2020.0423.
2
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.评估有资格接受和对检查点抑制剂免疫治疗药物有反应的美国癌症患者的百分比。
JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
3
FDA tightens indications for using long-acting and extended-release opioids to treat chronic pain.美国食品药品监督管理局收紧长效和缓释阿片类药物用于治疗慢性疼痛的适应症。
JAMA. 2013 Oct 16;310(15):1547-8. doi: 10.1001/jama.2013.280076.
4
Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.1999-2018 年获准上市的特定于上市前试验排除人群使用的抗生素。
Mayo Clin Proc. 2020 Dec;95(12):2699-2703. doi: 10.1016/j.mayocp.2020.07.023.
5
Medical physicists should not encourage or participate in off-label, non-FDA-approved uses of intravascular brachytherapy devices. For the proposition.医学物理学家不应鼓励或参与血管内近距离放射治疗设备的未标明用途、未获美国食品药品监督管理局批准的使用。对于该主张。
Med Phys. 2002 Sep;29(9):2128-9. doi: 10.1118/1.1501824.
6
Medical physicists should not encourage or participate in off-label, non-FDA-approved uses of intravascular brachytherapy devices. Against the proposition.医学物理学家不应鼓励或参与血管内近距离放射治疗设备的未获批准、非美国食品药品监督管理局（FDA）批准的使用。反对该提议。
Med Phys. 2002 Sep;29(9):2129-30. doi: 10.1118/1.1501824.
7
Attitudes of Italian liver transplantation centers toward the eligibility of controversial candidates.意大利肝脏移植中心对有争议候选人资格的态度。
Liver Transpl. 2014 Apr;20(4):497-8. doi: 10.1002/lt.23814. Epub 2014 Jan 27.
8
Reply: To PMID 23197388.回复：致PMID 23197388。
Liver Transpl. 2014 Apr;20(4):499. doi: 10.1002/lt.23835. Epub 2014 Feb 25.
9
COX-2 inhibitor safety in the workers' compensation market.环氧化酶-2抑制剂在工伤赔偿市场中的安全性。
Lippincotts Case Manag. 2005 Jul-Aug;10(4):217-20. doi: 10.1097/00129234-200507000-00008.
10
Association of Physician Peer Influence With Subsequent Physician Adoption and Use of Bevacizumab.医生间的同行影响力与随后医生对贝伐珠单抗的采用和使用的关联。
JAMA Netw Open. 2020 Jan 3;3(1):e1918586. doi: 10.1001/jamanetworkopen.2019.18586.

引用本文的文献

1
Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.接受靶向治疗的癌症患者的动脉和静脉血栓栓塞事件：一项基于人群的队列研究。
EClinicalMedicine. 2025 Aug 21;87:103440. doi: 10.1016/j.eclinm.2025.103440. eCollection 2025 Sep.
2
The impact of immune checkpoint inhibition on atherosclerosis in cancer patients.免疫检查点抑制对癌症患者动脉粥样硬化的影响。
Front Immunol. 2025 Jul 31;16:1604989. doi: 10.3389/fimmu.2025.1604989. eCollection 2025.
3
Diversity and inclusivity in oncology: A narrative review and orientation for institutional measures in Germany.

本文引用的文献

1
A reality check of the accelerated approval of immune-checkpoint inhibitors.免疫检查点抑制剂加速批准的现实审视。
Nat Rev Clin Oncol. 2019 Nov;16(11):656-658. doi: 10.1038/s41571-019-0260-y. Epub 2019 Aug 5.
2
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.评估有资格接受和对检查点抑制剂免疫治疗药物有反应的美国癌症患者的百分比。
JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.
肿瘤学中的多样性与包容性：德国机构措施的叙述性综述与指南
Transl Oncol. 2025 Oct;60:102493. doi: 10.1016/j.tranon.2025.102493. Epub 2025 Aug 8.
4
Causal relationships between immune-related adverse events, immune cell characteristics, and plasma metabolites: insights from Mendelian randomization study.免疫相关不良事件、免疫细胞特征与血浆代谢物之间的因果关系：孟德尔随机化研究的见解
Discov Oncol. 2025 Jul 1;16(1):1210. doi: 10.1007/s12672-025-02607-y.
5
Vaccines in cancer treatment and prevention: the time is now.癌症治疗与预防中的疫苗：时机已至。
J Clin Invest. 2025 Jul 1;135(13). doi: 10.1172/JCI195673.
6
Cancer Therapy-Related Cardiac Dysfunction in Patients Using Immune Checkpoint Inhibitors: A Multicenter Study.使用免疫检查点抑制剂患者的癌症治疗相关心脏功能障碍：一项多中心研究
JACC Asia. 2025 Jul;5(7):942-945. doi: 10.1016/j.jacasi.2025.04.009. Epub 2025 Jun 17.
7
Feasibility trial of Darwin OncoTreat and OncoTarget precision medicine testing to improve outcomes for patients with limited metastatic disease that failed first-line systemic therapy.达尔文肿瘤治疗与肿瘤靶点精准医学检测的可行性试验，旨在改善一线全身治疗失败的局限性转移性疾病患者的治疗效果。
PLoS One. 2025 Jun 11;20(6):e0325769. doi: 10.1371/journal.pone.0325769. eCollection 2025.
8
Revolutionizing breast cancer immunotherapy by integrating AI and nanotechnology approaches: review of current applications and future directions.通过整合人工智能和纳米技术方法革新乳腺癌免疫疗法：当前应用与未来方向综述
Bioelectron Med. 2025 May 30;11(1):13. doi: 10.1186/s42234-025-00173-w.
9
The Co-Creation of a Psychosocial Support Website for Advanced Cancer Patients Obtaining a Long-Term Response to Immunotherapy or Targeted Therapy.为晚期癌症患者共同创建一个心理社会支持网站，这些患者对免疫疗法或靶向疗法获得长期反应。
Curr Oncol. 2025 May 19;32(5):284. doi: 10.3390/curroncol32050284.
10
IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor Cells.IGM-7354，一种将白细胞介素15与抗程序性死亡配体1 IgM融合的免疫细胞因子，可诱导自然杀伤细胞和CD8 + T细胞介导的程序性死亡配体1阳性肿瘤细胞的细胞毒性。
Cancer Immunol Res. 2025 Aug 1;13(8):1172-1189. doi: 10.1158/2326-6066.CIR-24-0937.